发明名称 Modified MELK peptides and vaccines containing the same
摘要 Isolated peptides composed of the amino acid sequence of the modified MELK epitope peptide or immunologically active fragments thereof that bind to HLA antigens and have higher cytotoxic T lymphocyte (CTL) inducibility than that of the wild type MELK epitope peptide and thus are suitable for use in the context of cancer immunotherapy or endometriosis immunotherapy, more particularly cancer or endometriosis vaccines are described herein. The present invention further provides peptides that include one, two, or several amino acid insertions, substitutions or additions to the aforementioned peptides or fragments, but yet retain the requisite cytotoxic T cell inducibility. Further provided are nucleic acids encoding any of these aforementioned peptides as well as pharmaceutical substances and compositions including any of the aforementioned peptides or nucleic acids. The peptides, nucleic acids, pharmaceutical substances and compositions of this invention find particular utility in the treatment of cancers, tumors, and endometriosis.
申请公布号 US8871719(B2) 申请公布日期 2014.10.28
申请号 US201113574774 申请日期 2011.01.24
申请人 OncoTherapy Science, Inc. 发明人 Nakamura Yusuke;Tsunoda Takuya;Ohsawa Ryuji;Yoshimura Sachiko;Watanabe Tomohisa
分类号 A61K38/00;A61K39/00;C12N9/12;A61K39/39 主分类号 A61K38/00
代理机构 Kilpatrick Townsend & Stockton LLP 代理人 Kilpatrick Townsend & Stockton LLP
主权项 1. An isolated peptide that can bind to an HLA antigen and has cytotoxic T lymphocyte (CTL) inducibility, wherein the peptide consists of an amino acid sequence having one or more amino acid substitutions in the amino acid sequence of SEQ ID NO: 6 selected from the group consisting of (a) to (c): (a) the N-terminal amino acid, (b) the third amino acid from the N-terminus and (c) the third amino acid from the C-terminus.
地址 Kanagawa JP